Literature DB >> 12752577

Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-cutaneous and Costello syndromes.

M Tartaglia1, P D Cotter, G Zampino, B D Gelb, K A Rauen.   

Abstract

Costello syndrome (CS) is a rare, multiple congenital anomaly syndrome with characteristic dysmorphic features, cardiac anomalies and a tendency to develop certain cancers. Phenotypically there is some overlap with other genetic disorders, notably cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome (NS), suggesting that these syndromes may be allelic. We recently identified PTPN11, which encodes the non-receptor protein tyrosine phosphatase, SHP-2, as a major NS disease gene. In this report, we screened a cohort of 27 patients, with the clinical diagnosis of CS, for PTPN11 mutations using denaturing high performance liquid chromatography analysis. No mutations of the PTPN11 gene were found in the CS patients. Common polymorphisms in introns 6 and 7 and exon 8 were identified in four individuals. With our previous exclusion of PTPN11 mutations in CFC syndrome, these data suggest distinct genetic etiologies for Noonan, CFC and Costello syndromes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12752577     DOI: 10.1034/j.1399-0004.2003.00076.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

Review 1.  Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.

Authors:  Lakshmi Reddy Bollu; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.

Authors:  B Kerr; M-A Delrue; S Sigaudy; R Perveen; M Marche; I Burgelin; M Stef; B Tang; O B Eden; J O'Sullivan; A De Sandre-Giovannoli; W Reardon; C Brewer; C Bennett; O Quarell; E M'Cann; D Donnai; F Stewart; R Hennekam; H Cavé; A Verloes; N Philip; D Lacombe; N Levy; B Arveiler; G Black
Journal:  J Med Genet       Date:  2006-01-27       Impact factor: 6.318

Review 3.  The cardiofaciocutaneous syndrome.

Authors:  A Roberts; J Allanson; S K Jadico; M I Kavamura; J Noonan; J M Opitz; T Young; G Neri
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

4.  Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.

Authors:  Mark D Levin; Sulagna C Saitta; Karen W Gripp; Tara L Wenger; Jaya Ganesh; Jennifer M Kalish; Michael R Epstein; Rosemarie Smith; Richard J Czosek; Stephanie M Ware; Paula Goldenberg; Angela Myers; Kathryn C Chatfield; Matthew J Gillespie; Elaine H Zackai; Angela E Lin
Journal:  Am J Med Genet A       Date:  2018-07-28       Impact factor: 2.802

5.  Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.

Authors:  Bing Yu; Wei Liu; Wen-Mei Yu; Mignon L Loh; Shawn Alter; Olgun Guvench; Alexander D Mackerell; Li-Da Tang; Cheng-Kui Qu
Journal:  Mol Cancer Ther       Date:  2013-07-03       Impact factor: 6.261

Review 6.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.